Showing results (361-370 of 401) with videos related to
Sort By:
Pageof 41
Urologic Oncology|September 13, 2015
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activityNoah M Hahn, Beatrice S Knudsen, Siamak Daneshmand, et al.Nature|June 17, 2021
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Zoe June Assaf, Nicole Davarpanah, et al.World Journal of Urology|July 27, 2012
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?Michael Rink, Shahrokh F Shariat, Evanguelos Xylinas, et al.BJU International|December 11, 2024
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumourLuca Antonelli, Axel Heidenreich, Aditya Bagrodia, et al.Urology Practice|February 27, 2023
An Assessment Tool to Provide Targeted Feedback to Robotic Surgical Trainees: Development and Validation of the End-To-End Assessment of Suturing Expertise (EASE)Taseen F Haque, Alvin Hui, Jonathan You, et al.Urology Practice|May 3, 2023
Development and validation of an objective scoring tool to evaluate surgical dissection: Dissection Assessment for Robotic Technique (DART)Erik B Vanstrum, Runzhuo Ma, Jacqueline Maya-Silva, et al.BJU International|September 27, 2020
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinomaDavid D'Andrea, Surena Matin, Peter C Black, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual CancerLuca Antonelli, Davide Ardizzone, Isamu Tachibana, et al.Proceedings of the National Academy of Sciences of the United States of America|February 18, 2026
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancerMatthew D Galsky, Sudeh Izadmehr, Menggang Yu, et al.The Lancet. Oncology|March 15, 2021
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, et al.Pageof 41